RYZB Key Statistics, Chart & Performance
The current stock price of RYZB is 62.49 USD. In the past month the price increased by 0.66%.
RYZB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About RYZB
Company Profile
RayzeBio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California. The company went IPO on 2023-09-15. RayzeBio, Inc. is a vertically integrated radiopharmaceutical therapeutics company. The firm is focused on building a somatostatin receptor type 2 (SSTR2) franchise. The firm's drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225, an alpha particle radioisotope. In addition to its SSTR2 franchise, the Company has discovered a peptide that selectively binds to Glypican-3 (GPC3), an oncofetal protein selectively overexpressed in hepatocellular carcinoma (HCC) as well as other cancers. The firm is enrolled in a registrational Phase III clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients who have experienced progression of their cancer following treatment with Lu177 therapy.
Company Info
RAYZEBIO INC
5505 Morehouse Drive, Suite 300
San Diego CALIFORNIA US
Employees: 88
Phone: 16199372754
RAYZEBIO INC / RYZB FAQ
Can you describe the business of RAYZEBIO INC?
RayzeBio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California. The company went IPO on 2023-09-15. RayzeBio, Inc. is a vertically integrated radiopharmaceutical therapeutics company. The firm is focused on building a somatostatin receptor type 2 (SSTR2) franchise. The firm's drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225, an alpha particle radioisotope. In addition to its SSTR2 franchise, the Company has discovered a peptide that selectively binds to Glypican-3 (GPC3), an oncofetal protein selectively overexpressed in hepatocellular carcinoma (HCC) as well as other cancers. The firm is enrolled in a registrational Phase III clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients who have experienced progression of their cancer following treatment with Lu177 therapy.
What is the stock price of RAYZEBIO INC today?
The current stock price of RYZB is 62.49 USD. The price increased by 0.02% in the last trading session.
Does RYZB stock pay dividends?
RYZB does not pay a dividend.
What is the ChartMill rating of RAYZEBIO INC stock?
RYZB has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is RAYZEBIO INC (RYZB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RYZB.
What is the market capitalization of RYZB stock?
RAYZEBIO INC (RYZB) has a market capitalization of 3.81B USD. This makes RYZB a Mid Cap stock.
Who owns RAYZEBIO INC?
You can find the ownership structure of RAYZEBIO INC (RYZB) on the Ownership tab.
RYZB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RYZB.
RYZB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RYZB. RYZB has a great financial health rating, but its profitability evaluates not so good.
RYZB Financial Highlights
Over the last trailing twelve months RYZB reported a non-GAAP Earnings per Share(EPS) of -1.32. The EPS decreased by -29.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.12% | ||
| ROE | -12.71% | ||
| Debt/Equity | 0 |
RYZB Forecast & Estimates
11 analysts have analysed RYZB and the average price target is 54.4 USD. This implies a price decrease of -12.95% is expected in the next year compared to the current price of 62.49.